From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria.
Many subjects nowadays present with end-stage renal failure and its attendant cardiovascular complications without known prior renal damage. In this report we review the evidence available to strongly suggest that the present practice of secondary prevention in those with known prior renal disease should be extended to primary prevention for those subjects in the general population who are at risk for progressive renal failure, but who had never suffered from a primary renal disease. We show that such subjects can be detected by screening for albuminuria. Elevated urinary albumin loss is an indicator not only of poor renal, but also of poor cardiovascular prognosis. In addition to diabetic subjects who are at risk for albuminuria, we also show that hypertensive, obese, and smoking subjects are more susceptible. We suggest that therapies that have been shown to lower albumin excretion, such as ACE inhibitors, angiotensin II receptor antagonists, and statins be started early in such patients to prevent them from developing clinical renal disease and its attendant cardiovascular complications.
de Jong
Paul E
PE
University Hospital Groningen, Groningen Institute for Drug Exploration, Groningen, The Netherlands. p.e.de.jong@int.azg.nl
Brenner
Barry M
BM
D000419:Albuminuria / Q000175:diagnosis* / Q000503:physiopathology*; D018450:Disease Progression; D006801:Humans; D007676:Kidney Failure, Chronic / Q000503:physiopathology* / Q000517:prevention & control*; D008403:Mass Screening